UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.101

Sortiert nach

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

Annals of oncology, 2016-03, Vol.27 (3), p.379-390

2016

Volltextzugriff (PDF)

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women

Journal of clinical oncology, 1996-01, Vol.14 (1), p.78-84

1996

Volltextzugriff (PDF)

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

Annals of oncology, 1998-11, Vol.9 (11), p.1179-1184

1998

Volltextzugriff (PDF)

Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer

Journal of clinical oncology, 1999-10, Vol.17 (10), p.3058-3063

1999

Volltextzugriff (PDF)

Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma

Cancer, 2000-12, Vol.89 (11), p.2145-2152

2000

Volltextzugriff (PDF)

Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival

Annals of oncology, 2005-02, Vol.16 (2), p.267-272

2005

Volltextzugriff (PDF)

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

Journal of clinical oncology, 1993-01, Vol.11 (1), p.59-65

1993

Volltextzugriff (PDF)

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial

JNCI : Journal of the National Cancer Institute, 2007-02, Vol.99 (4), p.283-290

2007

Volltextzugriff (PDF)

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

The Lancet (British edition), 1994-05, Vol.343 (8909), p.1318-1321

1994

Volltextzugriff (PDF)

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

Journal of clinical oncology, 1995-03, Vol.13 (3), p.547-552

1995

Volltextzugriff (PDF)

Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer

Breast cancer research and treatment, 2003-11, Vol.82 (2), p.113-123

2003

Volltextzugriff (PDF)

Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials

Journal of clinical oncology, 2001-04, Vol.19 (7), p.1885-1892

2001

Volltextzugriff (PDF)

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas

Clinical cancer research, 1997-04, Vol.3 (4), p.593-600

1997

Volltextzugriff (PDF)

The case for clinical trials of tamoxifen for prevention of breast cancer

The Lancet (British edition), 1992-11, Vol.340 (8828), p.1145-1147

Powles, T.J.

1992

Volltextzugriff (PDF)

Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer

JNCI : Journal of the National Cancer Institute, 1998-05, Vol.90 (9), p.704-708

1998

Volltextzugriff (PDF)

Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation

Radiology, 1996-02, Vol.198 (2), p.333

1996

Volltextzugriff (PDF)

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study

Annals of oncology, 1996-09, Vol.7 (7), p.671-675

1996

Volltextzugriff (PDF)

Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

Breast cancer research and treatment, 1998-03, Vol.48 (1), p.11-20

1998

Volltextzugriff (PDF)

Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy

Annals of oncology, 1999-12, Vol.10 (12), p.1451-1455

1999

Volltextzugriff (PDF)

Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer : A pilot study

Breast cancer research and treatment, 1999, Vol.53 (1), p.51-59

1999

Volltextzugriff (PDF)

Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy

Breast cancer research and treatment, 2000, Vol.59 (2), p.171-175

2000

Volltextzugriff (PDF)

Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma

Cancer, 1999-05, Vol.85 (9), p.1996-2000

1999

Volltextzugriff (PDF)

A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast

European journal of cancer (1990), 1997-11, Vol.33 (13), p.2194-2197

1997

Volltextzugriff (PDF)

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

Cancer chemotherapy and pharmacology, 2004-04, Vol.53 (4), p.341-348

2004

Volltextzugriff (PDF)

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial

Breast cancer research and treatment, 2001, Vol.65 (2), p.125-134

2001

Volltextzugriff (PDF)

1 – 25 von 2.101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.912)
Mit Volltextzugriff
(1.926)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer

Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma

Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer

Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas

The case for clinical trials of tamoxifen for prevention of breast cancer

Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer

Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study

Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy

Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer : A pilot study

Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy

Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma

A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial

Suchergebnisse filtern